Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. Among authors: masszi t. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Anti-Inflammatory Cytokine Profiles in Thrombotic Thrombocytopenic Purpura-Differences Compared to COVID-19.
Demeter F, Bihari G, Vadicsku D, Sinkovits G, Kajdácsi E, Horváth L, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Masszi T, Vályi-Nagy I, Prohászka Z, Cervenak L. Demeter F, et al. Among authors: masszi t. Int J Mol Sci. 2024 Sep 17;25(18):10007. doi: 10.3390/ijms251810007. Int J Mol Sci. 2024. PMID: 39337495 Free PMC article.
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
Pour L, Micheva I, Usenko G, Mikala G, Masszi T, Simeonova K, Thuresson M, Huledal G, Norin S, Bakker NA, Minarik J. Pour L, et al. Among authors: masszi t. Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):e267-e275.e2. doi: 10.1016/j.clml.2024.02.012. Epub 2024 Feb 23. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38490927 Free article. Clinical Trial.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Schjesvold FH, et al. Among authors: masszi t. Haematologica. 2024 Jul 1;109(7):2331-2336. doi: 10.3324/haematol.2023.284635. Haematologica. 2024. PMID: 38426292 Free PMC article. Clinical Trial. No abstract available.
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
László T, Kotmayer L, Fésüs V, Hegyi L, Gróf S, Nagy Á, Kajtár B, Balogh A, Weisinger J, Masszi T, Nagy Z, Farkas P, Demeter J, Istenes I, Szász R, Gergely L, Sulák A, Borbényi Z, Lévai D, Schneider T, Pettendi P, Bodai E, Szerafin L, Rejtő L, Bátai Á, Dömötör MÁ, Sánta H, Plander M, Szendrei T, Hamed A, Lázár Z, Pauker Z, Radványi G, Kiss A, Körösmezey G, Jakucs J, Dombi PJ, Simon Z, Klucsik Z, Gurzó M, Tiboly M, Vidra T, Ilonczai P, Bors A, Andrikovics H, Egyed M, Székely T, Masszi A, Alpár D, Matolcsy A, Bödör C. László T, et al. Among authors: masszi t. J Pathol Clin Res. 2024 Jan;10(1):e351. doi: 10.1002/cjp2.351. Epub 2023 Nov 21. J Pathol Clin Res. 2024. PMID: 37987115 Free PMC article.
[How did the survival of acute myeloid leukemia change over the last ten years in our unit?].
Gaál L, Ruff E, Wiedemann Á, Svorenj S, Szita VR, Tóth AD, Masszi A, Horváth L, Szombath G, Nagy Z, Várkonyi J, Benedek S, Farkas P, Bödör C, Masszi T, Varga G. Gaál L, et al. Among authors: masszi t. Orv Hetil. 2023 Nov 12;164(45):1787-1794. doi: 10.1556/650.2023.32901. Print 2023 Nov 12. Orv Hetil. 2023. PMID: 37952177 Hungarian.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Dimopoulos MA, et al. Among authors: masszi t. Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0. Lancet Haematol. 2023. PMID: 37793771 Clinical Trial.
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Manzoor BS, Busman T, Pai M, Komlosi V, Anderson MA. Cochrane T, et al. Among authors: masszi t. Leuk Lymphoma. 2024 Nov;65(11):1743-1746. doi: 10.1080/10428194.2023.2247511. Epub 2023 Aug 25. Leuk Lymphoma. 2024. PMID: 37626019 No abstract available.
201 results